Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?

As of Oct. 22, 2026, IBB returned 37.7% over the trailing year versus 33.9% for PJP, while five-year growth of $1,000 favored PJP at $1,685 versus $1,352 for IBB. PJP had a lower five-year maximum drawdown (17.5% versus 39.8%), lower beta (0.42 versus 0.70), a higher dividend yield (0.92% versus 0.16%), but a higher expense ratio (0.58% versus 0.44%). The article frames IBB as broader biotech exposure and PJP as a more stable pharmaceutical-focused option, while noting rising interest rates and bond yields could pressure some cash-strapped biotech companies.

Analysis

The useful distinction is exposure to different earnings and financing regimes, not simply “safer” versus “riskier.” PJP’s pharma-heavy mix may be less exposed to biotech’s long-duration valuation sensitivity and external funding conditions, but it carries concentrated product, patent-expiry, and pricing-policy risks. IBB’s broader biotech basket can benefit more from successful pipeline readouts and deal activity, while higher real yields or tighter funding conditions can compress valuations and constrain smaller constituents. That creates a second-order divergence: financing stress can pressure biotech valuations even as larger pharmaceutical companies seek to acquire discounted assets, potentially benefiting well-capitalized acquirers but not necessarily the ETF broadly.

The reported historical drawdown and beta are backward-looking and do not establish future downside protection; nor do trailing returns justify chasing IBB’s recent relative strength. Gilead Sciences (GILD) appears in both baskets, so the relative trade is not a clean biotech-versus-pharma hedge. Verify current holdings, weights, and overlap before sizing; the article’s differing descriptions of PJP’s holding count also argue for checking the latest fund factsheets. No company-level conclusion follows from these ETF comparisons alone.

Near term, the signal is weak absent a change in rates or fund flows. Over 1–3 months, watch real yields, biotech financing conditions, and clinical or regulatory catalysts. Over 6–18 months, patent cycles, drug-pricing policy, and pipeline productivity should matter more than the expense-ratio gap. The contrarian point: PJP’s historical stability may reflect its past composition and period, not a durable defensive premium; IBB’s rebound may likewise overstate the durability of biotech breadth.

Key Decisions for Investors

• No immediate directional trade: the comparison is descriptive, and trailing performance is not a catalyst. Avoid switching allocations solely on the reported one-year return or historical drawdown.
• For a rates-driven relative-value expression, consider a small long PJP / short IBB position only if real yields rise and biotech funding or issuance weakens; reduce or exit if real yields fall materially, biotech financing improves, or IBB’s breadth strengthens. Confirm holdings overlap and borrow/liquidity first.
• For event-driven biotech upside, use IBB rather than treating it as a low-volatility healthcare allocation; size against potential drawdowns and track clinical readouts, regulatory decisions, and financing access across holdings.
• Before allocating to either ETF, verify current holdings and weights, actual overlap, tracking methodology, and distribution composition. Reassess the thesis if fund factsheets show materially different concentration or if relative performance reverses alongside improving biotech financing conditions.